Clinical Trial Supported by $2.1M ADDF Grant to Test Cancer Treatment in Alzheimer’s Patients

Clinical Trial Supported by $2.1M ADDF Grant to Test Cancer Treatment in Alzheimer’s Patients
The Alzheimer’s Drug Discovery Foundation (ADDF) announced that a Georgetown University Medical Center researcher has been awarded a $2.1 million grant to conduct a Phase 2 clinical trial of low-dose nilotinib (Tasigna, a cancer therapy) in patients with Alzheimer’s disease. The grant was awarded as part of the ADDF’s initiative “Learning from Cancer Advance Treatments for Neurodegenerative Diseases,” launched in 2015 with the goal of developing new therapies and testing existing cancer therapies for their potential in treating Alzheimer’s. Nilotinib is approved by the U.S. Food and Drug Administration (FDA) as a treatment for adult chronic myeloid leukemia (CML). Sc
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *